Stockscreener 앱 받기
20.73
3.98%
-0.86
시간 외 거래:
20.95
0.22
+1.06%
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Empowered Funds LLC Takes Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Baillie Gifford & Co. Sells 1,031,956 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics (DNLI) to Release Quarterly Earnings on Tuesday - MarketBeat
Mucopolysaccharidosis Market Analysis Across 7MM — Unveiling Growth Opportunities Across Different Types | DelveInsight - GlobeNewswire Inc.
Deutsche Bank sets $31 target for Denali Therapeutics stock - MSN
Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN
(DNLI) On The My Stocks Page - Stock Traders Daily
Denali Therapeutics (NASDAQ:DNLI) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.9%What's Next? - MarketBeat
abrdn plc Has $8.20 Million Stake in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Deutsche Bank Initiates Coverage of Denali Therapeutics (MUN:4DN) with Buy Recommendation - Nasdaq
Deutsche Bank Initiates Coverage of Denali Therapeutics (DNLI) with Buy Recommendation - Nasdaq
Deutsche Bank sets $31 target for Denali Therapeutics stock By Investing.com - Investing.com Australia
Stifel maintains Buy on Denali Therapeutics, $37 target - MSN
Stifel maintains Buy on Denali Therapeutics, $37 target By Investing.com - Investing.com Australia
Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) Price Target at $38.00 - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 6.2%What's Next? - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Short Interest Up 5.1% in January - MarketBeat
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study - MSN
Denali Therapeutics Announces Primary Analysis and - GlobeNewswire
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - Marketscreener.com
Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa - Marketscreener.com
Where are the Opportunities in (DNLI) - Stock Traders Daily
Leerink Partnrs Has Negative Outlook of DNLI FY2025 Earnings - MarketBeat
Zacks Research Has Bearish Estimate for DNLI FY2024 Earnings - MarketBeat
Denali Gains 26.6% in a Year: How Should You Play the Stock? - MSN
Denali Therapeutics Insiders Sold US$2.2m Of Shares Suggesting Hesitancy - Simply Wall St
What is Leerink Partnrs’ Forecast for DNLI FY2025 Earnings? - Defense World
Zacks Research Has Negative Outlook of DNLI FY2024 Earnings - Defense World
The Goldman Sachs Group Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $40.00 - MarketBeat
Alzheimer's Disease Therapeutics Market to Grow by USD 5.41 Billion (2024-2028), Novel Biomarker R&D Boosts Growth, with AI Driving Market TransformationTechnavio - The Malaysian Reserve
Denali Therapeutics Announces Upcoming Presentations on - GlobeNewswire
Revolutionary Brain Barrier Treatment for Hunter Syndrome Takes Center Stage at Major Medical Conference - StockTitan
The Goldman Sachs Group Has Lowered Expectations for Denali Therapeutics (NASDAQ:DNLI) Stock Price - Defense World
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 4.3%Time to Sell? - MarketBeat
How To Trade (DNLI) - Stock Traders Daily
0.27%
3.05%
자본화:
|
볼륨(24시간):